Show simple item record

dc.contributor.authorLeong, John M.
dc.contributor.authorRobbins, Douglas
dc.contributor.authorRosenfeld, Louis
dc.contributor.authorLahiri, Biswajit
dc.contributor.authorParveen, Nikhat
dc.date2022-08-11T08:10:03.000
dc.date.accessioned2022-08-23T16:53:24Z
dc.date.available2022-08-23T16:53:24Z
dc.date.issued1998-11-24
dc.date.submitted2008-07-15
dc.identifier.citationInfect Immun. 1998 Dec;66(12):6045-8.
dc.identifier.issn0019-9567 (Print)
dc.identifier.pmid9826395
dc.identifier.urihttp://hdl.handle.net/20.500.14038/42266
dc.description.abstractBorrelia burgdorferi, the Lyme disease agent, binds glycosaminoglycans (GAGs) such as heparin, heparan sulfate, and dermatan sulfate. Heparin or heparan sulfate fractions separated by size or charge were tested for their ability to inhibit attachment of B. burgdorferi to Vero cells. GAG chains of increasing length and/or charge showed increasing inhibitory potency, and detectable heparin inhibition of bacterial binding required a minimum of 16 residues. The ability of a given heparin fraction to inhibit binding to Vero cells was strongly predictive of its ability to inhibit hemagglutination, suggesting that hemagglutination reflects the capacity of B. burgdorferi to bind to GAGs.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=9826395&dopt=Abstract">Link to Article in PubMed</a>
dc.subjectAnimals
dc.subject*Bacterial Adhesion
dc.subjectBinding, Competitive
dc.subject*Borrelia burgdorferi
dc.subjectBorrelia burgdorferi Group
dc.subjectCercopithecus aethiops
dc.subjectGlycosaminoglycans
dc.subjectHemagglutination Tests
dc.subjectHeparin
dc.subjectStructure-Activity Relationship
dc.subjectVero Cells
dc.subjectMicrobiology
dc.subjectMolecular Genetics
dc.titleStructural requirements for glycosaminoglycan recognition by the Lyme disease spirochete, Borrelia burgdorferi
dc.typeJournal Article
dc.source.journaltitleInfection and immunity
dc.source.volume66
dc.source.issue12
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1628&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/629
dc.identifier.contextkey549058
refterms.dateFOA2022-08-23T16:53:24Z
html.description.abstract<p>Borrelia burgdorferi, the Lyme disease agent, binds glycosaminoglycans (GAGs) such as heparin, heparan sulfate, and dermatan sulfate. Heparin or heparan sulfate fractions separated by size or charge were tested for their ability to inhibit attachment of B. burgdorferi to Vero cells. GAG chains of increasing length and/or charge showed increasing inhibitory potency, and detectable heparin inhibition of bacterial binding required a minimum of 16 residues. The ability of a given heparin fraction to inhibit binding to Vero cells was strongly predictive of its ability to inhibit hemagglutination, suggesting that hemagglutination reflects the capacity of B. burgdorferi to bind to GAGs.</p>
dc.identifier.submissionpathoapubs/629
dc.contributor.departmentDepartment of Molecular Genetics and Microbiology
dc.source.pages6045-8


Files in this item

Thumbnail
Name:
9826395.pdf
Size:
112.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record